F.Hoffmann - La Roche Industry Symposium: Optimizing T-Cell Redirection: The Added Value of Costimulatory Bispecifics

Roche is pioneering costimulatory bispecifics targeting 4-1BB and CD28 to maximize the efficacy of T-cell bispecifics (TCBs) and enable chemotherapy-free regimens in early-line therapy. This session explores phase 1 biomarker data from FAP-4-1BBL, CD19-4-1BBL, and CD19-CD28 trials across solid and hematologic indications. We will present evidence of a costimulatory "Signal 2" mode of action and its contribution to clinical efficacy. Furthermore, we share findings on the distinct “personalities” of each costimulator, providing a roadmap for this emerging therapeutic class.